Why the study?
Heart failure is a leading cause of morbidity and mortality worldwide, but little is known regarding heart failure epidemiology and treatment in primary care.
What are the determinants of sacubitril/valsartan prescription and the prevalence of heart failure among patients treated by general practitioners?
Population
1288 heart failure patients treated by Swiss general practitioners
Design
Retrospective cross-sectional study
Authors
Loading...
Provides real-world HF treatment data in primary care; leaves open optimal sacubitril/valsartan implementation and outcomes.
What are the determinants of sacubitril/valsartan prescription and the prevalence of heart failure among patients treated by general practitioners?
In a Swiss primary care setting, heart failure prevalence was low (0.5%) and sacubitril/valsartan was prescribed in only 6% of patients, highlighting a need for increased awareness and optimization of guideline-directed medical therapy.
Rachamin et al. (2020) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: